Literature DB >> 19845545

How does chronic sildenafil prevent vascular oxidative stress in insulin-resistant rats?

Alexandra Oudot1, Delphine Behr-Roussel, Olivier Le Coz, Sarah Poirier, Jacques Bernabe, Laurent Alexandre, François Giuliano.   

Abstract

INTRODUCTION: Insulin resistance features both endothelial dysfunction and increased oxidative stress. Both disorders are targeted by a chronic treatment with sildenafil. However, the mechanism of action by which chronic sildenafil exerts its effects on reactive oxygen species sources is still largely unknown. AIM: We therefore investigated how chronic sildenafil administration could impact vascular endothelial NO and superoxide release in a rat model of insulin resistance induced by fructose overload.
METHODS: Adult male Wistar rats were fed a fructose-enriched diet (fructose-fed rats [FFR]) for 9 weeks. From weeks 6-8, sildenafil was administered subcutaneously twice daily (20 mg/kg), followed by a 1-week washout. MAIN OUTCOME MEASURES: Vascular endothelial NO and superoxide release were monitored in vitro in thoracic aortic segments using oxidative fluorescence. Specific inhibitors were used to distinguish the respective role of the main superoxide-producing systems within the vascular wall (i.e., mitochondrial respiratory chain and NADPH oxidases). The levels of expression of eNOS, Akt, and NADPH oxidase subunits were determined in the abdominal aorta.
RESULTS: Chronic sildenafil administration corrected hyperglycemia, hyperinsulinemia, and hypertriglyceridemia in FFR. Moreover, after 9 weeks of diet, while global unstimulated aortic endothelial NO and superoxide release were unchanged in FFR, the relative contribution of the mitochondrial respiratory chain and NADPH oxidases was modified. Chronic sildenafil treatment, even after the 1-week washout period, was able to increase endothelial NO release independently of Akt-dependent phosphorylation by up-regulating eNOS expression, and restored the relative contribution of each superoxide-producing system examined, yielding endothelial superoxide release. Finally, in vitro incubation of aortic segments with sildenafil markedly decreased the endothelial aortic superoxide release.
CONCLUSIONS: The present study showed that chronic sildenafil produced sustained vascular antioxidant effects in insulin-resistant rats by increasing NO release and regulating vascular superoxide release, supporting therefore further investigations using chronic sildenafil administration in preventing cardiovascular alterations associated with oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845545     DOI: 10.1111/j.1743-6109.2009.01551.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  4 in total

1.  A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer's Disease.

Authors:  Niyatee Samudra; Michael Motes; Hanzhang Lu; Min Sheng; Ramon Diaz-Arrastia; Michael Devous; John Hart; Kyle B Womack
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

2.  Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis.

Authors:  Biljana Musicki; Trinity J Bivalacqua; Hunter C Champion; Arthur L Burnett
Journal:  J Sex Med       Date:  2013-11-20       Impact factor: 3.802

Review 3.  Role of curcumin in ameliorating hypertension and associated conditions: a mechanistic insight.

Authors:  Priyanka Joshi; Sushil Joshi; Deepak Kumar Semwal; Kanika Verma; Jaya Dwivedi; Swapnil Sharma
Journal:  Mol Cell Biochem       Date:  2022-05-15       Impact factor: 3.842

4.  Subcutaneous Administration of a Nitric Oxide-Releasing Nanomatrix Gel Ameliorates Obesity and Insulin Resistance in High-Fat Diet-Induced Obese Mice.

Authors:  Guang Ren; Patrick Tae Joon Hwang; Reid Millican; Juhee Shin; Brigitta C Brott; Thomas van Groen; Craig M Powell; Sushant Bhatnagar; Martin E Young; Ho-Wook Jun; Jeong-A Kim
Journal:  ACS Appl Mater Interfaces       Date:  2022-04-25       Impact factor: 10.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.